IL-33-activated ILC2s induce tertiary lymphoid structures in pancreatic cancer

Masataka, Amisaki, Abderezak, Zebboudj, Hiroshi, Yano, Siqi Linsey, Zhang, George, Payne, Adrienne Kaya, Chandra, Rebecca, Yu, Pablo, Guasp, Zachary M., Sethna, Akihiro, Ohmoto, Luis A., Rojas, Charlotte, Cheng, Theresa, Waters, Alexander, Solovyov, Stephen, Martis, Ashley S., Doane, Charlotte, Reiche, Emmanuel M., Bruno, Martina, Milighetti, Kevin, Soares, Zagaa, Odgerel, John Alec, Moral, Julia N., Zhao, Mithat, Gönen, Rui, Gardner, Alexei V., Tumanov, Abdul G., Khan, Olivia, Vergnolle, Elisabeth K., Nyakatura, Ivo C., Lorenz, Manuel, Baca, Erin, Patterson, Benjamin, Greenbaum, David, Artis, Taha, Merghoub, Vinod P., Balachandran

Nature |

Tertiary lymphoid structures (TLSs) are de novo ectopic lymphoid aggregates that regulate immunity in chronically inflamed tissues, including tumours. Although TLSs form due to inflammation-triggered activation of the lymphotoxin (LT)–LTβ receptor (LTβR) pathway1, the inflammatory signals and cells that induce TLSs remain incompletely identified. Here we show that interleukin-33 (IL-33), the alarmin released by inflamed tissues2, induces TLSs. In mice, Il33 deficiency severely attenuates inflammation- and LTβR-activation-induced TLSs in models of colitis and pancreatic ductal adenocarcinoma (PDAC). In PDAC, the alarmin domain of IL-33 activates group 2 innate lymphoid cells (ILC2s) expressing LT that engage putative LTβR+ myeloid organizer cells to initiate tertiary lymphoneogenesis. Notably, lymphoneogenic ILC2s migrate to PDACs from the gut, can be mobilized to PDACs in different tissues and are modulated by gut microbiota. Furthermore, we detect putative lymphoneogenic ILC2s and IL-33-expressing cells within TLSs in human PDAC that correlate with improved prognosis. To harness this lymphoneogenic pathway for immunotherapy, we engineer a recombinant human IL-33 protein that expands intratumoural lymphoneogenic ILC2s and TLSs and demonstrates enhanced anti-tumour activity in PDAC mice. In summary, we identify the molecules and cells of a druggable pathway that induces inflammation-triggered TLSs. More broadly, we reveal a lymphoneogenic function for alarmins and ILC2s.